Home
8 items | 4 visits
interesting tidbits about health, home, misc, may add to things you probably didn't know but are pretty amazed to find out.
Updated on 2009-09-28
Created on 2009-05-21
Category: Health & Wellness
URL:
-
Rome Was Built in a Day, with Hundreds of Thousands of Digital Photos
Previous versions of the Photo Tourism software matched each photo to every other photo in the set. But as the number of photos increases the number of matches explodes, increasing with the square of the number of photos. A set of 250,000 images would take at least a year for 500 computers to process, Agarwal said. A million photos would take more than a decade.
-
Previous versions of the Photo Tourism software matched each photo to every other photo in the set. But as the number of photos increases the number of matches explodes, increasing with the square of the number of photos. A set of 250,000 images would take at least a year for 500 computers to process, Agarwal said. A million photos would take more than a decade.
-
-
Elsevier: Article Locator
-
Oncolytic Viruses: A New Weapon to Fight Cancer
Journal of Medical Imaging and Radiation Sciences, Volume 39, Issue 3, Pages 115-127
C. Brown, J. Bell
-
-
Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer - Full Text View - ClinicalTrials.gov
-
Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer
-
-
CNW Telbec | JENNEREX, INC. | Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
-
Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Researc
-
The company's lead product JX-594, currently in
an international Phase 2 trial for primary liver cancer, demonstrated
promising Phase 1 efficacy and safety results in patients with a diverse array
of common large market cancers. Jennerex's products target, attack and
eradicate cancers through a novel and potent oncolytic mechanism that is
dependent on highly-specific replication of the company's poxviruses in cancer
cells. These products simultaneously stimulate the body's immune response to
the cancer. Of note, this mechanism of action and the results in patients to
date put the company's product class in a leadership position. Jennerex
Biotherapeutics was established in San Francisco and in Ottawa in 2006 with
Dr. David Kirn (CEO) in San Francisco and Dr. John Bell (CSO) from the Ottawa
Hospital Research Institute/University of Ottawa. For more information about
Jennerex and the company's robust pipeline and three clinical-stage products,
please visit www.jennerex.com.
-
-
China Approves World's First Oncolytic Virus Therapy For Cancer Treatment-International cancer treatment centre
Study done in spring of 2008
-
it still killed tumor cells preferentially and was superior to chemotherapy alone
-
In its phase III trial, Sunway reported a 79% response rate for H101 plus chemotherapy, compared with 40% for chemotherapy alone.
- 4 more annotations...
-
1 - 8 of 8
Showing 20▼ items per page
List Comments
(0)
List Info
Sponsored Links
Ads by Google